Choosing between Pharmacy and Biotechnology after Class 12 requires understanding their distinct career paths. Pharmacy ...

The CBSE Class 12 Biology exam is scheduled for March 27, 2026. Experts advise students to focus on key topics like Genetics, ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

In the fast-paced world of biotechnology, success hinges on more than groundbreaking science—it requires the right connections, strategic partnerships, and access to capital. Biotech Showcase delivers ...

The US Congress is poised to enact bipartisan legislation that would block some Chinese biotechnology companies from government-funded contracts and authorize the Trump administration to bar US ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Preview this article 1 min The Beverly biotech is working ...

Dec 10 (Reuters) - French biotech company Abivax's (ABVX.PA), opens new tab shares rose by over 20% on Wednesday on market rumours that U.S. pharma giant Eli Lilly (LLY.N), opens new tab could make an ...

The iShares Biotechnology ETF is up over 32% in six months on rate cut expectations and potential sector rotation. The State Street SPDR S&P Biotech ETF has surged 45% in six months but remains 27% ...

Chai Discovery, a biotech startup with backing from OpenAI, announced a $130 million Series B round at a $1.3 billion valuation on Monday. The round was led by General Catalyst and Oak HC/FT, the ...

Swiss oncology powerhouse BeOne Medicines (ONC) has emerged as one of 2025's top performers in a sector often plagued by volatility. Year-to-date, ONC shares have rocketed 75%, outpacing many peers ...

Investor Martin Shkreli’s big biotech short position is blowing up after the stock’s monumental rally over the past week, following a major clinical catalyst. Popularly known as “Pharma bro,” Shkreli ...